This was accomplished by adoptively transferring and tracking CD8+ T cells from Thy1.1+ pmel-1 TCR transgenic mice, which are specific for the melanoma antigen gp100, into C57BL/6 (Thy1.2+) mice 1 day prior to B16 challenge. This evidence concerns the gene CD8A and melanoma.